Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovine-derived heparin
- Development stage
- Preclinical
- Lead developer
- Changshan Kaijiejian Biopharma
- Modality
- Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Ovine-derived heparin refers to a suite of anticoagulant products, including heparin sodium and enoxaparin sodium, derived from sheep intestinal mucosa. Developed by Changshan Kaijiejian Biopharma, these products serve as Halal and Kosher-compliant alternatives to traditional porcine-derived heparin. The mechanism of action involves binding to antithrombin III, which significantly accelerates the inactivation of clotting factors such as Factor Xa and thrombin (Factor IIa), thereby inhibiting the coagulation cascade. These sheep-derived variants are intended for use in general anticoagulation and are currently in the pharmaceutical research stage.
- Other names
- 羊源肝素Ovine-derived heparin sodiumOvine-derived enoxaparin sodium
02
Targets
ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on ovine-derived heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovine-derived heparin.